Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid for reducing blood loss in pediatric hip osteotomy
NL-OMON59211Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hip dysplasia (DDH), Slipped Capital Femoral Epiphysis (SCFE), Legg-Calvé-Perthes disease (LCPD) and 1 more comparing Tranexamic acid with Placebo (2 arms). Primary endpoint: Estimated intraoperative blood loss. Started Apr 2023; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
hip dysplasia (DDH)Slipped Capital Femoral Epiphysis (SCFE)Legg-Calvé-Perthes disease (LCPD)muscle diseases (NMD)
Beyond the preview
Go deeper on NL-OMON59211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59211.